Drug Profile

UI 014

Alternative Names: UI-014

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Korea United Pharm Inc
Class Antihyperlipidaemics
Mechanism of Action Apolipoprotein C-III inhibitors; Lipoprotein lipase stimulants; Peroxisome proliferator-activated receptor alpha agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 May 2024 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea (PO, Tablet)
24 May 2022 Phase-I development is ongoing in South Korea (Korea United Pharm pipeline, May 2022)
28 Oct 2021 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea (PO, Tablet)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com